Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting

被引:52
|
作者
Maggio, Emilia [1 ]
Sartore, Mauro [1 ]
Attanasio, Marcella [1 ]
Maraone, Giorgia [2 ]
Guerriero, Massimo [3 ]
Polito, Antonio [1 ]
Pertile, Grazia [1 ]
机构
[1] Sacro Cuore Don Calabria Hosp, Via Don Sempreboni 5, I-37024 Verona, Italy
[2] Sapienza Univ Rome, UOC Ophthalmol, Dept Med Surg Sci & Biotechnol, Terracina, Italy
[3] Univ Verona, Dept Comp Sci, Verona, Italy
关键词
RANIBIZUMAB PLUS PROMPT; ANTI-VEGF-TREATMENT; VISUAL-ACUITY; INTRAVITREAL AFLIBERCEPT; RETINAL THICKNESS; INITIAL TREATMENT; DEFERRED LASER; FACTOR THERAPY; OUTCOMES; BEVACIZUMAB;
D O I
10.1016/j.ajo.2018.08.004
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To report the long-term outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME) in a realworld clinical setting and to assess the efficacy of subsequent alternative treatments in eyes with suboptimal response to anti-VEGF. DESIGN: Retrospective interventional case series. METHODS: The medical records of consecutive eyes with center-involving DME, treated between August 2008 and June 2015 with 3 monthly intravitreal antiVEGF injections-with or without prompt or deferred laser-followed by pro re nata re-treatment, were reviewed. A subgroup of eyes that were unresponsive to the treatment received subsequent alternative therapeutic options, including switching to another anti-VEGF drug, intravitreal injection of dexamethasone, and vitrectomy. RESULTS: A total of 170 eyes of 129 patients were included in the study. The mean follow-up (FU) was 45.6 months (SD 18; minimum 12-maximum 81). The change in mean best-corrected visual acuity (BCVA) at 1-year FU was +5 ETDRS letters (P < .0001). Improvement in BCVA was statistically significant up to 5 years. Improvement in central macular thickness (CMT) was statistically significant up to the last FU visit. In eyes with suboptimal response, no significant visual improvement was found by switching to another antiVEGF (P = .4347). Twenty-four eyes treated with intravitreal dexamethasone and 14 with vitrectomy exhibited a significant reduction in CMT with variable functional responses. In these eyes, better BCVA gain was found in cases with an early change of the treatment strategy. CONCLUSION: The results support treatment with intravitreal anti-VEGF for DME in real-world clinical settings and suggest that an early change of the therapeutic strategy should be considered for eyes unresponsive to the treatment. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:209 / 222
页数:14
相关论文
共 50 条
  • [31] Predictive factors for patients receiving intravitreal anti-vascular endothelial growth factor for the treatment of diabetic macular edema
    Carroll, Robert M.
    Yu, Yinxi
    VanderBeek, Brian L.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2020, 30 (01) : 72 - 80
  • [32] Commentary: Switching of anti-vascular endothelial growth factor agents in refractory diabetic macular edema
    Ratra, Dhanashree
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2021, 69 (02) : 367 - 368
  • [33] Diabetic Macular Edema Management: A Review of Anti-Vascular Endothelial Growth Factor (VEGF) Therapies
    Cheema, Abdullah A.
    Cheema, Haider R.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (01)
  • [34] Foveal thickness reduction after anti-vascular endothelial growth factor treatment in chronic diabetic macular edema
    Willmann, Gabriel
    Nepomuceno, Antonio Brunno
    Messias, Katharina
    Barroso, Leticia
    Scott, Ingrid U.
    Messias, Andre
    Jorge, Rodrigo
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2017, 10 (05) : 760 - 764
  • [35] Foveal thickness reduction after anti-vascular endothelial growth factor treatment in chronic diabetic macular edema
    Gabriel Willmann
    Antonio Brunno Nepomuceno
    Katharina Messias
    Leticia Barroso
    Ingrid U.Scott
    André Messias
    Rodrigo Jorge
    International Journal of Ophthalmology, 2017, (05) : 760 - 764
  • [36] Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema
    Koyanagi, Yoshito
    Yoshida, Shigeo
    Kobayashi, Yoshiyuki
    Kubo, Yuki
    Nakama, Takahito
    Ishikawa, Keijiro
    Nakao, Shintaro
    Hisatomi, Toshio
    Ikeda, Yasuhiro
    Oshima, Yuji
    Ishibashi, Tatsuro
    Sonoda, Koh-hei
    OPHTHALMOLOGICA, 2018, 239 (2-3) : 94 - 102
  • [37] Budget Impact Analysis of Anti-vascular Endothelial Growth Factor in Patients with Diabetic Macular Edema
    Yang, Jangmi
    Shin, Sang Jin
    Suh, Jae Kyung
    Tchoe, Hajin
    Cho, Songhee
    Kang, Min Joo
    Jee, Donghyun
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2019, 60 (07): : 667 - 675
  • [38] Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema Does Flavor Matter?
    Apte, Rajendra S.
    JAMA OPHTHALMOLOGY, 2018, 136 (03) : 269 - 270
  • [39] Timing of Switching to Steroid Implants in Cases of Recalcitrant Diabetic Macular Edema Not Responding to Anti-vascular Endothelial Growth Factor (VEGF) Therapy: A Real-World Study
    Raizada, Seemant
    Al Kandari, Jamal
    AL Diab, Fahad
    Al Sabah, Khalid
    Kumar, Niranjan
    Mathew, Sebastian
    AL Dafiri, Yousef
    Jaleel, Talal Abdul
    Alrabiah, Mahmoud
    Al Ajmi, Mohammad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
  • [40] Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factor: Considerations Related to Nonimprovers
    Hodzic-Hadzibegovic, Delila
    Sander, Birgit Agnes
    Valerius, Marianne
    Lund-Andersen, Henrik
    OPHTHALMOLOGY RETINA, 2018, 2 (11): : 1133 - 1142